Stockholm, October 25, 2017 - Redeye today has initiated analyst coverage of Isofol Medical, a Swedish biotech company developing a first-line treatment of advanced colorectal cancer. The company was founded based on the research of Professor Bengt Gustavsson, one of the researchers behind the current gold standard.
We believe that the share of Isofol Medical at the moment is neglected by the market. Following a weak post-IPO development, where short-sighted investors have put pressure on the share, the market value of the firm has deviated far from the company’s intrinsic value. With several interesting catalysts in the coming year, our analyst Arvid Necander motivates a considerable upside potential in the stock, valuing the company at SEK 38 per share in Base Case.
In our Redeye Rating model, Isofol Medical has a strong ownership profile, with insiders represented among the largest shareholders. The company has several institutional owners among the major shareholders. With a high average tenure and experience from different industries, management is also well equipped to take Isofol through the ongoing trials and into a commercialization phase.
Redeye är specialister på Life Science och Technology. Vi har en ledande marknadsposition inom aktieanalys, Corporate Finance och Corporate Broking. Våra klienter är snabbväxande framtidsföretag på den nordiska marknaden. Vår research utgår från en värdebaserad investeringsfilosofi och en unik ratingmodell. Redeye grundades 1999, är ett auktoriserat värdepappersbolag och står under Finansinspektionens tillsyn.
Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading providers of Corporate Broking and Corporate Finance in these sectors. Our clients are innovative growth companies in the Nordics and we use a unique Rating model built on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).